YY1抑制效应的破坏可促进人乳头瘤病毒16型癌基因的转录

人乳头瘤病毒１６型（ＨＰＶ１６）癌基因的表达受病毒早期启动子Ｐ９７的控制。位于ＬＣＲ上ＹＹ１蛋白结合位点的破坏可明显提高Ｐ９７的活性。为了观测ＹＹ１位点破坏在全基因组范围内对病毒ｅ６／ｅ７基因转录的影响,将构建的带有ＬＣＲ特异性突变的重组ＨＰＶ１６全基因组ＤＮＡ和ＨＰＶ１６野毒株ＤＮＡ转染至培养细胞,同时组建ＨＰＶ１６Ｅ６反向序列ＲＮＡ体外转录质粒。ＲＮａｓｅ保护试验证实,突变ＨＰＶ１６ＤＮＡ在短     

人乳头瘤病毒16型长控制区上YY1结合位点的破坏可增强病毒诱导细胞？…

细胞转当因子ＹＹ１可抑制人乳头瘤病毒１６型癌基因启动子Ｐ９７的活性,ＹＹ１位点的突变和缺失不仅可诱导Ｐ９７活性增强而且可在全基因组内增强Ｅ６癌基因转录,同时使病毒对啮齿类动物纤维细胞的转化能力增强。为了观测人乳头瘤病毒１６型长控制区序列上ＹＹ１蛋白特异性结合位点破坏在完整基因组范围内对人原代包皮角源细胞永生化能力的影响,将ＨＰＶ１６ ＹＹ１位点突变体和野毒株转染至人原代包皮角源细胞。     

用PCR扩增和克隆鸡传染性贫血病毒全基因组DNA

根据已发表的序列,分别在鸡贫血病毒（ＣＡＶ）环形基因组ＤＮＡ（全长２．３ｋｂ）的ＥｃｏＲＩ位点和ＢａｍＨＩ位点的两侧选择适当序列合成两对引物,用ＰＣＲ技术,从斑点杂交检测到病毒核酸的ＣＡＶ感染的ＭＤＣＣＲＰ１细胞基因组ＤＮＡ中,分别扩增出包含ＥｃｏＲＩ和ＢａｍＨＩ分割开的病毒基因组两部分（１．５ｋｂ和０．８ｋｂ）约１．５ｋｂ和约１．２５ｋｂ的两个片段。再将其中相应序列拼接克隆进ｐＵＣ１８载体,获得包含ＣＡＶ全基因组序列ＤＮＡ片段的克隆质粒ｐＣＡＶ２．４。酶切分析表明,该质粒具有预期的ＢａｍＨＩ位点、ＰｓｔＩ位点、ＨｉｎｄⅢ位点,而预期的ＥｃｏＲＩ位点消失。重组质粒插入ＤＮＡ片段的两端序列分析表明,质粒ｐＣＡＶ２．４是包含ＣＡＶ全基因组序列的重组质粒,插入ＤＮＡ片段序列中的ＥｃｏＲＩ位点序列发生了一个碱基突变。     

柯萨奇B3病毒结构和非结构蛋白基因重组质粒的构建及其在体外真核细胞中的

制备ＣＶＢ３结构蛋白和非结构蛋白重组质粒ＤＮＡ疫苗时,采用ＲＴ－ＰＣＲ从ＣＶＢ感染的ＨｅＬａ细胞中扩增ＶＰ１、ＶＰ２、２Ａ和３Ｄ基因,重组入真核表达质粒ｐｃＤＮＡ３中,构建ｐｃＤＮＡ３／ＶＰ２、ｐｃＤＮＡ３／ＶＰ１、ｐｃＤＮＡ３／２Ａ和ｐｃＤＮＡ３／３Ｄ重组质粒,经酶切和测下实扩增的序列并将各重组质粒体外转染真核细胞ＣＯＳ－７,用ＲＴ－ＰＣＲ检测ｍＲＮＡ的转录,用Ｗｅｓｔｅｒｎ－ｂｌｏｔ检测表达产物。结果４种重组质粒酶切出相应大小的目的片段,经测序证实为ＣＶＢ３相应序列,Ｗｅｓｔｅｒｎ－ｂｌｏｔ证实能够在体外真核细胞中表达。本文成功构建ＣＶＢ３结构与非结构蛋白的重组质粒ＤＮＡ疫苗,为进一步研究其免疫效果奠定了基础。     

湖北地区宫颈癌组织中人乳头瘤病毒16型E7基因的分离,克隆和序…

采用加端聚合链反应技术,从湖北地区一宫颈癌患者癌组织ＤＮＡ中分离出人乳头瘤病毒１６型（ＨＰＶ１６）Ｅ７基因,并在ｐＵＣ１８载体中克隆,经限生核酸内切酶分析和ＤＮＡ序列分析,确认了含ＨＰＶ１６Ｅ７重组克隆质粒,命名ｐｆＨＰＶ１６Ｅ７－ＨＢ。ＤＮＡ序列分析表明,ＨＰＶ１６Ｅ７－ＨＢ基因全长２９４ｂｐ（与报道的标准基因长度相同）但其核苷酸顺序中的两处发生了Ｃ－（Ｔ）突变,即第４３位密码子ＣＡＡ变为ＴＡＡ     

人乳头瘤病毒16型E6基因的T—A克隆及在真核细胞中的表达

由于ＨＰＶ１６Ｅ６蛋白能诱导机体保护性免疫反应,可作为基因治疗的靶抗原。用杆状病毒昆虫细胞表达系统制备了ＨＰＶ１６Ｅ６基因工程蛋白,拟用于宫颈癌细胞系小鼠模型抗癌的免疫治疗。用ＰＣＲ技术从ＨＰＶ１６基因组中扩增获得转化基因Ｅ６的完整ＯＲＦ,按ＴＡ策略将其克隆到自行制备的杆状病毒转移载体ｐＶＬ１３９３Ｔ尾载体中,置于杆状病毒ＡｃＭＮＰＶＰｏｌｈ晚期启动子控制之下,用此重组转移质粒ｐＶＬ１３９３Ｅ６与杆状病毒ＤＮＡ共转染昆虫细胞Ｓｆ９,经噬斑筛选获得带有编码Ｅ６蛋白基因的重组杆状病毒株,并在昆虫细胞Ｓｆ９中表达为非融合性Ｅ６蛋白。ＳＤＳＰＡＧＥ电泳分析其分子量约为１８ｋＤ,免疫印迹实验表明,此重组蛋白能被兔抗ＨＰＶ１６Ｅ６抗体所识别。     

湖北地区宫颈癌组织中人乳头瘤病毒16型E7基因的分离、克隆和序列分析

采用加端聚合酶链反应技术,从湖北地区一宫颈癌患者癌组织ＤＮＡ中分离出人乳头瘤病毒１６型（ＨＰＶ１６）Ｅ７基因,并在ｐＵＣ１８载体中克隆。经限制性核酸内切酶分析和ＤＮＡ序列分析,确认了含ＨＰＶ１６Ｅ７重组克隆质粒,命名ｐＨＰＶ１６Ｅ７─ＨＢ。ＤＮＡ序列分析表明,ＨＰＶ１６Ｅ７─ＨＢ基因全长２９４ｂｐ（与报道的标准株基因长度相同）,但其核苷酸顺序中有两处发生了Ｃ→Ｔ突变,即第４３位密码子ＣＡＡ变为ＴＡＡ,第７６位ＣＧＴ变为ＴＧＴ;前者使谷氨酰胺密码子变为终止密码,即无义奕变（ｎｏｎｓｅｎｓｅｍｕｔａｔｉｏｎ）。这种突变发生在２９４个碱基的ＤＮＡ扩增产物之中,不像是ＰＣＲ本身的错配,而很可能是湖北株与标准株之间的结构差异。     

人乳头瘤病毒16碧蓝晚期基因L1在大肠杆菌中的表达

人乳头瘤病毒（ＨＰＶ）感染与宫颈癌的发生关系密切。其晚期蛋白Ｌ１是主要结构蛋白,可以刺激机体产生中和抗体,对病毒攻击可以起到保护作用。本研究将ＨＰＶ１６型中国分离株的Ｌ１基因定向克隆到原核表达载体ｐＥＴ－２１ｃ质粒中,建立ＨＰＶ１６ Ｌ１在大肠杆菌中的高效表达系统ｐＥＴ２１ｃ－ＨＰＶ１６ Ｌ１,该系统在ＩＰＴＧ的诱导下可表达６０ｋｕ的Ｌ１蛋白,表达效率为２３％,此蛋白通过Ｗｅｓｔｅｒｎ－ｂｌｏｔ得     

HIV—1核蛋白p24在昆虫细胞中的表达

将完整的ＨＩＶ－１ ｐ２４基因克隆到杆状病毒转移质粒中,使用重组转移质粒与野生型杆状病毒ＤＮＡ共转染Ｓｆ９昆虫细胞,经筛选获得带有编码ｐ２４基因的重组杆状病毒。重组杆状病毒感染Ｓｆ９细胞后在细胞中表达了ＨＩＶ核蛋白ｐ２４。其重组蛋白的分子量为２４ｋＤ。此重组糖蛋白在免疫荧光,免疫印染和酶联免疫实验中都能被人ＨＩＶ－１阳性血清和单克隆抗体所识别。     

A组轮状病毒我国地方株VP6基因的序列测定及其在杆状病毒系统中的表达

通过反转录－ 聚合酶链反应（ Ｒ Ｔ－ Ｐ Ｃ Ｒ） 获得了轮状病毒地方株 Ｔ１１４ Ｖ Ｐ６ 全基因的ｃ Ｄ Ｎ Ａ 片段,将其克隆入转移载体质粒ｐ Ｖ Ｌ１３９３ 中,构建成重组质粒ｐ Ｖ Ｌ１３９３ － Ｖ Ｐ６ 。对克隆的 Ｖ Ｐ６ 基因进行序列测定,并用它和杆状病毒（ Ａｃ Ｍ Ｎ Ｐ Ｖ） 野毒株 Ｄ Ｎ Ａ 共转染 Ｓｆ９ 细胞,筛选纯化得到含 Ｖ Ｐ６ 基因插入片段的重组杆状病毒,并进行了表达重组蛋白 Ｖ Ｐ６ 的检测。测序结果显示 Ｖ Ｐ６ 基因全长１ ３５６ｂｐ ,序列分析显示与 Ｗａ 株非常接近,提示 Ｔ１１４ 为亚组Ⅱ病毒株。用高价免疫血清经 Ｗｅｓｔｅｒｎ ｂｌｏｔ 检测表达产物,结果显示,重组病毒感染细胞裂解液样品中可见大小约４５ｋ Ｄ 的特异条带;亚组Ⅱ特异性单抗检测到大小约１２０ｋ Ｄ 的条带,提示重组蛋白 Ｖ Ｐ６ 获得了表达,具有正常的抗原反应性和天然 Ｖ Ｐ６ 的三体结构。     

人乳头瘤病毒16型长控制区上YY1结合位点的破坏可增强病毒诱导细胞永生化能力

细胞转录调节因子 Ｙ Ｙ１ 可抑制人乳头瘤病毒１６ 型（ Ｈ Ｐ Ｖ １６） 癌基因启动子 Ｐ９７ 的活性, Ｙ Ｙ１ 位点的突变和缺失不仅可诱导 Ｐ９７ 活性增强而且可在全基因组内增强 Ｅ６ 癌基因转录,同时使病毒对啮齿类动物纤维细胞的转化能力增强。为了观测人乳头瘤病毒１６ 型长控制区（ Ｈ Ｐ Ｖ１６ Ｌ Ｃ Ｒ） 序列上 Ｙ Ｙ１ 蛋白特异性结合位点破坏在完整基因组范围内对人原代包皮角源细胞永生化能力的影响,将 Ｈ Ｐ Ｖ １６ Ｙ Ｙ１ 位点突变株和野毒株转染至人原代包皮角源细胞。筛选结果表明,突变株可诱导形成永生化细胞,永生化能力明显高于野毒株。对４ 株永生化细胞系 Ｄ Ｎ Ａ检测发现,均含有呈整合状态的 Ｈ Ｐ Ｖ １６ Ｄ Ｎ Ａ,其中３ 株的 Ｅ１／ Ｅ２ 区域有缺失。 Ｒ Ｎ Ａ 检测显示,４株细胞内均有 Ｅ６／ Ｅ７ ｍ Ｒ Ｎ Ａ 的转录。这表明, Ｈ Ｐ Ｖ １６ Ｌ Ｃ Ｒ 上 Ｙ Ｙ１ 蛋白特异性结合位点的破坏,可在完整基因组范围内增强病毒使人原代包皮角源细胞永生化的能力。     

Comparison of the structure and DNA-binding properties of the E2 proteins from an oncogenic and a non-oncogenic human papillomavirus

Human papillomaviruses (HPVS) that infect the genital tract can be divided into two groups: high-risk HPV types, such as HPV 16 and HPV 18, are associated with cancer, low-risk HPV types, such as HPV 6, are associated with benign warts. In both high-risk and low-risk HPV types, the papillomavirus E2 protein binds to four sites within the viral long control region (LCR) and regulates viral gene expression. Here, we present the crystal structure of the minimal DNA-binding domain (DBD) from the HPV 6 E2 protein. We show that the HPV 6 E2 DBD is structurally more similar to the HPV 18 and bovine papillomavirus type 1 (BPV1) E2 proteins than it is to the HPV 16 E2 protein. Using gel retardation assays, we show that the hierarchy of E2 sites within the HPV 16 and HPV 6 LCRs are different. However, despite these differences in structure and site preference, both the HPV 16 and 6 E2 DBDs recognise an extended version of the consensus E2 binding site derived from studies of the BPV1 E2 protein. In both cases, the preferred binding site is 5'AACCGN(4)CGGTT3', where the additional flanking base-pairs are in bold and N(4) represents a four base-pair central spacer. Both of these HPV proteins bind preferentially to E2 sites that contain an A:T-rich central spacer. We show that the preference for an A:T-rich central spacer is due, at least in part, to the need to adopt a DNA conformation that facilitates protein contacts with the flanking base-pairs.     

Sequence duplication and internal deletion in the integrated human papillomavirus type 16 genome cloned from a cervical carcinoma.

Integrated human papillomavirus type 16 (HPV16) sequences were cloned from a cervical carcinoma and analyzed by restriction mapping and nucleotide sequencing. The viral integration sites were mapped within the E1 and E2 open reading frames (ORFs). The E4 and E5 ORFs were entirely deleted. An internal deletion of 376 base pairs (bp) was found disrupting the L1 and L2 ORFs. Sequencing analysis showed that an AGATGT/ACATCT inverted repeat marked the deletion junction with two flanking direct repeats 14 and 8 bp in length. A 1,330-bp sequence duplication containing the long control region (LCR) and the E6 and E7 ORFs was also found. The duplication junction was formed by two 24-bp direct repeats with 79% (19 of 24) homology located within the LCR and the E2 ORF of the prototype viral genome, respectively. This observation leads us to propose that the initial viral integration involved an HPV16 dimer in which the direct repeats in tandem units recombined, resulting in reiteration of only a portion of the original duplication. A guanosine insertion between nucleotides 1137 and 1138 created a continuous E1 ORF which was previously shown to be disrupted. Results from this study indicate that sequence reiteration and internal deletion in the integrated, and possibly in the episomal, HPV16 genome are influenced by specific nucleotide sequences in the viral genome. Moreover, reiteration of the LCR/E6/E7 sequences further supports the hypothesis that the E6/E7 ORFs may code for oncogenic proteins and that regulatory signals in the LCR may play a role in cellular transformation.     

HPV-2E2蛋白(A338V)突变体对E2蛋白DNA结合能力增强的研究

HPV-2是引起皮肤寻常疣的常见HPV型别,病毒E2蛋白可抑制病毒早期启动子的活性。我们曾经报道来自一例巨大寻常疣患者的HPV-2突变E2蛋白对病毒早期启动子活性的抑制作用明显减弱,该E2蛋白在其C末端的DNA结合区域带有A338V的点突变。本研究利用原核表达系统表达纯化了突变E2(A338V)和HPV-2原毒株的羧基端和全长蛋白。电泳迁移率实验结果显示,E2蛋白可与带有E2蛋白特异性结合位点的寡核苷酸探针形成复合物,突变E2蛋白比原毒株E2蛋白的DNA结合能力强。这提示DNA结合能力的增强可能为E2蛋白对病毒启动子活性影响的分子基础,与患者出现罕见巨大寻常疣这一临床表型关联。     

The use of a human papillomavirus 18 promoter for tissue-specific expression in cervical carcinoma cells

The use of tissue-specific promoter elements in the treatment of cervical cancer has been explored in this paper. The P₁₀₅ promoter of human papillomavirus 18 (HPV18) was utilised to direct tissue-specific expression in a number of cell types. Expression was examined in three cervical carcinoma cell lines: HeLa (HPV18 positive), SiHa (HPV16 positive), and C33A cells (HPV negative); the epithelial cell line, H1299; and the foetal fibroblast cell line, MRC5, utilising a luciferase expression vector. Expression was highest in the cervical cell lines by a factor of at least 80. The effect of a number of mutations in the P₁₀₅ promoter on expression levels was examined. Three deletion constructs of the long control region (LCR) were investigated: an 800 bp fragment (LCR800), a 400 bp fragment (LCR400), and a 200 bp fragment (LCR200), as well as the full length product LCR of HPV18 (LCR1000). The LCR800 construct of the HPV18 P₁₀₅ promoter had the highest level of expression in the cervical cell lines and was also highest in the HPV18-positive HeLa cell line. Site-directed mutagenesis was then employed on the LCR800 construct to create four further constructs that each had inactivating mutations in one of the four E2 binding sites (E2BSs). Overall, this study indicated that the LCR800 construct of the HPV18 P₁₀₅ promoter could be utilised as a tissuerestricted promoter in cervical cancer cells.